Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cullinan Oncology, Inc.
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
March 01, 2024
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology to Participate in Upcoming Investor Conferences
February 27, 2024
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 18, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
December 14, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
November 03, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology to Participate in Upcoming Investor Conferences
October 30, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology to Participate in Upcoming Investor Conferences
September 06, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
August 09, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology to Participate in Upcoming Investor Conferences
July 31, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
May 25, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
April 26, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
April 20, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
March 27, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
March 14, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 09, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
February 27, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
February 13, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
February 02, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
January 24, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
November 02, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Cullinan Oncology to Participate in Upcoming Investor Conferences
November 01, 2022
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Tickers
CGEM
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.